ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2684

Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR2 Antibodies As Surrogate Markers for CNS Disease Severity in SLE

Shunsei Hirohata, Yoshiyuki Arinuma and Eisuke Ogawa, Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies, central nervous system involvement, interleukins (IL), neuropsychiatric disorders and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Neuropsychiatric manifestations occur in approximately one-half of patients with SLE and may cause substantial impairment of quality of life as well as disability. Among a variety of neuropsychiatric manifestations in SLE, acute confusional state (ACS) in diffuse psychiatric/neuropsychological syndromes (diffuse NP-SLE) is the most serious one. Of note, cerebrospinal fluid (CSF) IL-6 was found to be elevated in patients with NP-SLE, including diffuse NP-SLE and focal NP-SLE. Moreover, recent studies have demonstrated that CSF anti-NMDA receptor NR2 antibodies (anti-NR2) are associated with diffuse NP-SLE. However, the relationship of CSF IL-6 and anti-NR2 with the severity of NP-SLE remains uncertain. The current studies examined whether CSF IL-6 and ant-NR2 might be surrogate markers for the severity of NP-SLE.

Methods: CSF samples were obtained from 62 SLE patients who satisfied the 1982 ACR revised criteria when they showed active neuropsychiatric manifestations (44 patients with diffuse NP-SLE and 18 patients with neurologic syndromes [focal NP-SLE]) as well as from 20 control patients with non-inflammatory neurological diseases. CSF IL-6 was quantitated by bioassay using IL-6 dependent cell line MH60.BSF2.CSF IgG anti-NR2 were measured by ELISA using synthetic peptide containing the extracellular ligand-binding domain of NR2.

Results: CSF IL-6 was significantly elevated in diffuse NP-SLE compared with that in focal NP-SLE or in control patients. CSF anti-NR2 were also significantly elevated in diffuse NP-SLE compared with those in focal NP-SLE or in control patients (figure). Moreover, CSF IL-6 levels as well as CSF anti-NR2 were also significantly higher in ACS than in diffuse NP-SLE other than ACS (cognitive disorder, mood disorder, anxiety disorder and psychosis). Finally, CSF IL-6 levels were significantly correlated with CSF anti-NR2 in patients with NP-SLE (r=0.3732, p=0.0054).

Conclusion: These results demonstrate that CSF IL-6 as well as CSF anti-NR2 were most markedly elevated in ACS. The data therefore indicate that CSF IL-6 and anti-NR2 might be surrogate markers for the disease severity of NP-SLE. Finally, the positive correlation between CSF IL-6 and anti-NR2 suggest that anti-NR2 might be involved in the production of IL-6 within the CNS in SLE.


Disclosure:

S. Hirohata,
None;

Y. Arinuma,
None;

E. Ogawa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cerebrospinal-fluid-il-6-and-anti-nmda-receptor-nr2-antibodies-as-surrogate-markers-for-cns-disease-severity-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology